NRXP Relative Valuation
NRXP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NRXP is overvalued; if below, it's undervalued.
Historical Valuation
No Data
Competitors Valuation Multiple
The average P/S ratio for NRXP's competitors is 7.08, providing a benchmark for relative valuation. NRX Pharmaceuticals Inc Corp (NRXP) exhibits a P/S ratio of 0.62, which is -91.22% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
People Also Watch
MSFT
Microsoft Corp
454.270
USD
+0.25%
NVDA
NVIDIA Corp
135.400
USD
+0.42%
WMT
Walmart Inc
98.240
USD
+1.96%
AVGO
Broadcom Inc
228.610
USD
-1.73%
TSLA
Tesla Inc
349.980
USD
+2.09%
ORCL
Oracle Corp
160.490
USD
+0.68%
XOM
Exxon Mobil Corp
108.190
USD
-0.36%
AMZN
Amazon.com Inc
205.590
USD
+0.20%
AAPL
Apple Inc
211.260
USD
-0.09%
META
Meta Platforms Inc
640.340
USD
-0.55%
FAQ
Is NRX Pharmaceuticals Inc (NRXP) currently overvalued or undervalued?
NRX Pharmaceuticals Inc (NRXP) is now in the Fair zone, suggesting that its current forward PS ratio of 0.62 is considered Fairly compared with the five-year average of 0.07. The fair price of NRX Pharmaceuticals Inc (NRXP) is between to according to relative valuation methord.
What is NRX Pharmaceuticals Inc (NRXP) fair value?
How does NRXP's valuation metrics compare to the industry average?
What is the current P/B ratio for NRX Pharmaceuticals Inc (NRXP) as of May 19 2025?
What is the current FCF Yield for NRX Pharmaceuticals Inc (NRXP) as of May 19 2025?
What is the current Forward P/E ratio for NRX Pharmaceuticals Inc (NRXP) as of May 19 2025?